{"id":479802,"date":"2020-04-16T18:28:01","date_gmt":"2020-04-16T18:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=479802"},"modified":"2020-04-16T18:28:01","modified_gmt":"2020-04-16T18:28:01","slug":"postherpetic-neuralgia-epidemiology-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/postherpetic-neuralgia-epidemiology-forecast-2030_479802.html","title":{"rendered":"Postherpetic Neuralgia Epidemiology Forecast, 2030"},"content":{"rendered":"
\"Postherpetic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Postherpetic Neuralgia – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Postherpetic Neuralgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

DelveInsight’s ‘Postherpetic Neuralgia – Epidemiology Forecast to 2030<\/strong><\/a>‘ report delivers an in-depth understanding of the disease, historical and forecasted Postherpetic Neuralgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

\"\"<\/strong><\/p>\n

The key facts of the report:<\/strong>
1. People over 60 years of age have about a 60% chance while people 70 or older have about a 75% chance of developing Postherpetic Neuralgia after getting shingles.
2. Postherpetic Neuralgia incidence is about 5% among patients with herpes zoster in their 60s, reaching about 10% among those in their 80s.
3. In Japan, people aged 65 years or older already number 23 million, accounting for 18% of the total population.<\/p>\n

Key benefits of the report:
<\/strong>1. Postherpetic Neuralgia market report covers a descriptive overview and comprehensive insight of the Postherpetic Neuralgia Epidemiology and Postherpetic Neuralgia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Postherpetic Neuralgia market report provides insights on the current and emerging therapies.
3. Postherpetic Neuralgia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Postherpetic Neuralgia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Postherpetic Neuralgia market.<\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-epidemiology-forecast<\/p>\n

Scope of the Report:
<\/strong>1. The Postherpetic Neuralgia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
2. The Postherpetic Neuralgia Epidemiology Report and Model provide an overview of the risk factors and global trends of Postherpetic Neuralgia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
3. The report provides insight about the historical and forecasted patient pool of Postherpetic Neuralgia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
4. The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
5. The report assesses the disease risk and burden and highlights the unmet needs of Postherpetic Neuralgia
6. The report provides the segmentation of the Postherpetic Neuralgia epidemiology<\/p>\n

Reasons to buy:
<\/strong>1. The Postherpetic Neuralgia Epidemiology report will allow the user to –
2. Develop business strategies by understanding the trends shaping and driving the global Postherpetic Neuralgia market
3. Quantify patient populations in the global Postherpetic Neuralgia market to improve product design, pricing, and launch plans
4. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Postherpetic Neuralgia therapeutics in each of the markets covered
5. Understand the magnitude of Postherpetic Neuralgia population by its epidemiology
6. The Postherpetic Neuralgia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources<\/p>\n

Download free sample pages: https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-epidemiology-forecast<\/strong><\/p>\n

Table of contents:<\/strong><\/p>\n

1. Key Insights<\/span> <\/p>\n

2. Executive Summary of Postherpetic Neuralgia<\/span><\/p>\n

3. Postherpetic Neuralgia: Disease Background and Overview<\/span><\/p>\n

3.1. Introduction<\/span><\/p>\n

3.2. Sign and Symptoms<\/span><\/p>\n

3.3. Pathophysiology<\/span><\/p>\n

3.4. Risk Factors<\/span><\/p>\n

3.5. Diagnosis<\/span><\/p>\n

4. Patient Journey<\/span><\/p>\n

5. Epidemiology and Patient Population<\/span><\/p>\n

5.1. Epidemiology Key Findings<\/span><\/p>\n

5.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

5.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

5.3.1. Postherpetic Neuralgia Epidemiology Scenario in the 7MM (2017- 2030)<\/span><\/p>\n

5.4. United States Epidemiology<\/span><\/p>\n

5.4.1. Postherpetic Neuralgia Epidemiology Scenario in the United States (2017- 2030)<\/span><\/p>\n

5.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

5.5.1. Germany Epidemiology<\/span><\/p>\n

5.5.1.1. Postherpetic Neuralgia Epidemiology Scenario in Germany (2017- 2030)<\/span><\/p>\n

5.5.2. France Epidemiology<\/span><\/p>\n

5.5.2.1. Postherpetic Neuralgia Epidemiology Scenario in France (2017- 2030)<\/span><\/p>\n

5.5.3. Italy Epidemiology<\/span><\/p>\n

5.5.3.1. Postherpetic Neuralgia Epidemiology Scenario in Italy (2017- 2030)<\/span><\/p>\n

5.5.4. Spain Epidemiology<\/span><\/p>\n

5.5.4.1. Postherpetic Neuralgia Epidemiology Scenario in Spain (2017- 2030)<\/span><\/p>\n

5.5.5. United Kingdom Epidemiology<\/span><\/p>\n

5.5.5.1. Postherpetic Neuralgia Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

5.6. Japan Epidemiology<\/span><\/p>\n

5.6.1. Postherpetic Neuralgia Epidemiology Scenario in Japan (2017- 2030)<\/span><\/p>\n

6. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

6.1. Postherpetic Neuralgia Treatment and Management<\/span><\/p>\n

6.2. Postherpetic Neuralgia Treatment Algorithm<\/span><\/p>\n

7. KOL Views<\/span><\/p>\n

8. Unmet Needs<\/span><\/p>\n

9.  Appendix<\/span><\/p>\n

9.1. Bibliography<\/span><\/p>\n

9.2. Report Methodology<\/span><\/p>\n

10. DelveInsight Capabilities<\/span><\/p>\n

11. Disclaimer<\/span><\/p>\n

12. About DelveInsight<\/span><\/p>\n

*The table of contents is not exhaustive; will be provided in the final report<\/em><\/span><\/p>\n

About DelveInsight:<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Contact us:<\/strong>
Shruti Thakur
info@delveinsight.com
+919650213330<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s ‘Postherpetic Neuralgia – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Postherpetic Neuralgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-479802","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/479802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=479802"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/479802\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=479802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=479802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=479802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}